| Tevimbra (tislelizumab-jsgr) / BeiGene |
| Recruiting | 2 | 23 | RoW | Tislelizumab, BGB-A317, Afatinib | West China Hospital | Head and Neck Cancer | 08/23 | 08/24 | | |
NCT04992143: TACE+Tilelizumab+Sorafenib in the Treatment of BCLC Stage C HCC |
|
|
| Recruiting | 2 | 20 | RoW | TACE, Tilelizumab, Sorafenib | First Affiliated Hospital of Zhejiang University, BeiGene (Beijing) Co., Ltd | BCLC Stage C Hepatocellular Carcinoma | 08/23 | 12/23 | | |
ChiCTR2000035275: Phase II clinical study of Tislelizumab combined with radiotherapy in the treatment of non muscle invasive bladder cancer after BCG treatment failure |
|
|
| Not yet recruiting | 2 | 50 | China | Tislelizumab combined with radiotherapy | Sun Yat-Sen University Cancer Center ; Sun Yat-Sen University Cancer Center, BeiGene Biotechnology Co., Ltd | Bladder cancer | | | | |
| Not yet recruiting | 2 | 37 | NA | sitravatinib, tislelizumab | Beijing Cancer Hospital | Melanoma | 09/23 | 09/23 | | |
BGB-A317-214, NCT05116085: Efficacy and Safety of Tislelizumab (BGB-A317) as Neo-Adjuvant Treatment in Patients With Colorectal Cancer |
|
|
| Active, not recruiting | 2 | 33 | RoW | Tislelizumab, BGB-A317 | BeiGene | Colorectal Cancer | 09/23 | 01/27 | | |
ChiCTR2200056693: Tislelizumab Combined With Bevacizumab for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer:a single-arm, phase 2 study. |
|
|
| Not yet recruiting | 2 | 30 | | None | Taizhou hospital; Taizhou hospital, Beigene | lung cancer | | | | |
Wfeng-001, NCT05231850: A Phase II Study of Tislelizumab as Adjuvant Therapy for Patients With Stage Ⅱ and Stage Ⅲ Colon Cancer and dMMR/MSI. |
|
|
| Not yet recruiting | 2 | 70 | NA | Tislelizumab | The First Affiliated Hospital of Zhengzhou University | Colon Cancer | 09/23 | 09/27 | | |
NCT05724329: Neoadjuvant Tislelizumab in Combination With Dasatinib and Quercetin in Resectable HNSCC (COIS-01) |
|
|
| Recruiting | 2 | 24 | RoW | Tislelizumab + Dasatinib + Quercetin (neoadjuvant), surgery, Tislelizumab + Dasatinib + Quercetin (adjuvant) | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Head and Neck Squamous Cell Carcinomas | 06/24 | 12/27 | | |
| Recruiting | 2 | 40 | RoW | PD-1 with chemotherapy, upright surgery | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Oral Cancer, PD-1 | 08/27 | 08/30 | | |
NCT05878028: L-TIL Plus Tislelizumab for PD1 Antibody Resistant aNSCLC |
|
|
| Recruiting | 2 | 33 | RoW | L-TIL, Tislelizumab, Docetaxel, Liquid Tumor Infiltrating Lymphocytes | Quanli Gao | Non-small Cell Lung Cancer | 09/25 | 09/25 | | |
ChiCTR2100050763: A single-center, single-arm clinical study of gemcitabine combined with cisplatin or carboplatin followed by tislelizumab for neoadjuvant treatment of selective myometrial invasive bladder urothelial carcinoma |
|
|
| Recruiting | 2 | 30 | China | Tilelizumab combined with cisplatin, gemcitabine | Liaoning Cancer Hospital and Institute ; Liaoning Cancer Hospital and Institute, BeiGene (Beijing) Biotechnology Co., Ltd. sponsored a funding of 200,000 yuan and a donation of 320 medicines | Bladder urothelial carcinoma | | | | |
CASTLE-02, NCT05057845: Cryoablation Combined With Tislelizumab Plus Lenvatinib as Second-line or Later Therapy in Advanced Hepatocellular Carcinoma |
|
|
| Recruiting | 2 | 25 | RoW | Tislelizumab, lenvatinib, US/CT-guided Percutaneous Cryoablation | Fudan University | Advanced Hepatocellular Carcinoma | 09/23 | 09/24 | | |
| Recruiting | 2 | 40 | RoW | Tisleizumab(BGB-A317), surgery | Sun Yat-sen University | DMMR Colorectal Cancer, Anti PD-1, Immunotherapy | 11/24 | 12/25 | | |
NCT04821765: Study of PD-1 Antibody Combined With Chemoradiotherapy in Oligometastatic Esophageal Cancer |
|
|
| Recruiting | 2 | 35 | RoW | PD-1 antibody, Chemoradiation, Albumin-Bound Paclitaxel, Cisplatin | Chinese Academy of Medical Sciences | Esophagus Cancer, Chemoradiotherapy, Oligometastatic Disease, Immunotherapy | 09/23 | 09/23 | | |
SEEK-01, NCT05807542: Neoadjuvant Immunotherapy Combined With Chemotherapy in Patients With Locally Advanced ESCC |
|
|
| Completed | 2 | 20 | RoW | Tislelizumab, Paclitaxel-albumin, Carboplatin | Shanghai Zhongshan Hospital | Esophagus Cancer | 09/23 | 04/24 | | |
NCT05536102: The Effectiveness and Safety of XELOX and Tislelizumab + PLD for Resectable Gastric Cancer (LidingStudy) |
|
|
| Recruiting | 2 | 38 | RoW | PLD, Pegylated Liposomal Doxorubicin, Oxaliplatin, Eloxatin, Capecitabine, Xeloda, Tislelizumab, BGB-A317 | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | Gastric Cancer | 09/23 | 09/27 | | |
NCT05519865: A Study of Tucidinostat Combined With Tislelizumab as First-line Treatment in Advanced NSCLC |
|
|
| Recruiting | 2 | 114 | RoW | Tucidinostat, Chidamide, CS055, Tislelizumab | Chipscreen Biosciences, Ltd. | Non Small Cell Lung Cancer | 10/23 | 10/24 | | |
NCT06284746: Tirelizumab Combined With Chemotherapy in the Treatment of HER-2 Negative Locally Advanced Gastric Cancer |
|
|
| Recruiting | 2 | 80 | RoW | Tirolizumab+SOX/XELOX, SOX/XELOX | Lin Chen | Locally Advanced Gastric Carcinoma, HER2 Negative, Efficacy, Safety | 04/25 | 07/25 | | |
NCT05192681: Tislelizumab as Cross-line Treatment for Advanced NSCLC |
|
|
| Enrolling by invitation | 2 | 35 | RoW | Tislelizumab, Docetaxel | Fujian Cancer Hospital | Advanced Non-small-cell Lung Cancer | 10/23 | 10/23 | | |
ChiCTR2200056784: Tislelizumab Plus Chemotherapy for Neoadjuvant Treatment of Resectable Non-small Cell Lung Cancer |
|
|
| Recruiting | 2 | 100 | | Tislelizumab Plus Chemotherapy ，Q3W | Sun Yat-sen University Cancer Center; Sun Yat-sen University Cancer Center, self-funding and company support | non-small cell lung cancer | | | | |
NCT05092217: Tirelizumab Plus Surgery vs Surgery Alone for Recurrent Nasopharyngeal Carcinoma |
|
|
| Not yet recruiting | 2 | 80 | NA | Tirelizumab, PD-1 antibody, salvage surgery | Eye & ENT Hospital of Fudan University | Nasopharyngeal Carcinoma | 10/23 | 10/24 | | |
NCT05323890: Tislelizumab Combined With Neoadjuvant Radiotherapy and Chemotherapy for Resectable Esophageal Squamous Cell Carcinoma. |
|
|
| Recruiting | 2 | 15 | RoW | Tislelizumab Combined With Neoadjuvant Radiotherapy and Chemotherapy, Anti-PD-1 Therapy | Shandong Cancer Hospital and Institute | Advanced Esophageal Squamous Cell Cancer | 10/23 | 10/24 | | |
NCT05545124: Study of Donafenib Combined With Tislelizumab in the Adjuvant Treatment of Primary HCC With High Risk of Recurrence |
|
|
| Not yet recruiting | 2 | 32 | NA | Donafenib + Tislelizumab | Henan Cancer Hospital | Hepatocellular Carcinoma | 11/23 | 11/24 | | |
NCT06134193: Combination Therapy of HAIC, Surufatinib and Tislelizumab for Unresectable or Metastatic Biliary Tract Cancer |
|
|
| Not yet recruiting | 2 | 41 | NA | HAIC, Surufatinib, Tislelizumab | Wuhan Union Hospital, China | Carcinoma, Intrahepatic Cholangiocarcinoma, Gallbladder Cancer, Surufatinib, Angiogenesis Inhibitors, Tislelizumab, Antineoplastic Agents, Immunological, Immunotherapy | 06/24 | 06/25 | | |
NCT04902261: Tislelizumab Combined With Nab-paclitaxel and Gemcitabine for Recurrent Pancreatic Cancer |
|
|
| Recruiting | 2 | 140 | RoW | Tislelizumab, Nab paclitaxel, Gemcitabine | Changhai Hospital | Recurrent Pancreatic Cancer | 11/23 | 11/23 | | |
NCT05172440: A Study on the Safety and Effectiveness of Tislelizumab Combined With Axitinib for Neoadjuvant Treatment of ccRCC |
|
|
| Active, not recruiting | 2 | 20 | RoW | tislelizumab combined with axitinib | Hongqian Guo | Neoadjuvant Therapy | 11/23 | 10/24 | | |
B2023-153, NCT06130007: A Prospective, Single-arm Phase II Clinical Trial of Tislelizumab Combined With Platinum Doublet Neoadjuvant Therapy to Improve Mandibular Preservation in Resectable Locally Advanced Oral Squamous Cell Carcinoma. |
|
|
| Not yet recruiting | 2 | 48 | NA | Three-Week Treatment Regimen with Trastuzumab in Combination with Docetaxel and Platinum Triple Therapy | Xuekui Liu | Oral Squamous Cell Carcinoma | 09/24 | 10/24 | | |
NCT06132698: Immune Checkpoint Inhibitors Intrathecal Injection in Patients With Leptomeningeal Metastases in NSCLC |
|
|
| Not yet recruiting | 2 | 17 | NA | Tislelizumab, pemetrexed | West China Hospital | NSCLC Associated With Leptomeningeal Metastases | 11/24 | 11/25 | | |
CLL-RT1, NCT04271956: Efficacy and Safety of Zanubrutinib Plus Tislelizumab for Treatment of Patients With Richter Transformation |
|
|
| Active, not recruiting | 2 | 57 | Europe | Tislelizumab, BGB-A317, Zanubrutinib, BGB-3111 | German CLL Study Group | Richter Transformation | 12/23 | 12/24 | | |
ChiCTR2100043836: Anlotinib hydrochloride combined with tirelizumab, paclitaxel liposome and nedaplatin in a single-arm, single-center, phase II exploratory clinical study of preoperative neoadjuvant therapy for esophageal squamous cell carcinoma |
|
|
| Recruiting | 2 | 20 | China | Anlotinib capsule combined with tirelizumab, paclitaxel liposome and nedaplatin | The First Affiliated Hospital of Guangxi Medical University ; The First Affiliated Hospital of Guangxi Medical University, Baiji Shenzhou (Beijing) Biological Technology Co. Ltd, Chia Tai Tianqing Pharmaceutical Group Co. LTD | Esophageal cancer | | | | |
NCT04969029: Immunotherapy Versus Chemotherapy as Adjuvant Therapy for Colon Cancer With MSI-H or POLE/ POLD1 Mutations |
|
|
| Recruiting | 2 | 30 | RoW | Tirelizumab | Tianjin Medical University Cancer Institute and Hospital | Immunotherapy, Adjuvant Therapy, Colon Cancer, MSI-H | 12/23 | 12/24 | | |
BGB-A317-212, NCT05014828: To Evaluate the Efficacy and Safety of Tislelizumab in Combination With Lenvatinib in Patients With Selected Solid Tumors |
|
|
| Active, not recruiting | 2 | 65 | RoW | lenvatinib, Tislelizumab, BGB-A317 | BeiGene | Advanced Solid Tumor | 10/23 | 07/24 | | |
NCT05394233: Tislelizumab +Bevacizumab+pc for Untreated EGFR+ and High PD-L1 Non-squamous NSCLC |
|
|
| Not yet recruiting | 2 | 20 | RoW | Tislelizumab Combined With Bevacizumab and Platinum Plus Pemetrexed | Sichuan Cancer Hospital and Research Institute | Non-squamous Non-small Cell Lung Cancer, EGFR Gene Mutation | 12/23 | 06/24 | | |
Rebirth, NCT05531123: Risk-stratification Based Bladder-sparing Modalities for Muscle-invasive Bladder Cancer |
|
|
| Recruiting | 2 | 30 | RoW | Tislelizumab, gemcitabine and cisplatin, Modified hypofractionation | Fudan University | Bladder Cancer | 12/23 | 12/24 | | |
NCT05690035: Tislelizumab Combined With Fruquintinib for Metastatic pMMR/MSS Colorectal Cancer |
|
|
| Not yet recruiting | 2 | 12 | RoW | Tislelizumab & Fruquintinib | Sun Yat-sen University, Hutchmed, BeiGene | Metastatic Colorectal Cancer, mCRC | 12/23 | 01/26 | | |
PPIO-004-EC001, NCT05880082: PPIO-004 Clinical Application of Efficacy Prediction Model Based on Epigenomics Sequencing Technology in Neoadjuvant Immunotherapy for Esophageal Cancer |
|
|
| Enrolling by invitation | 2 | 62 | RoW | Tislelizumab, Carboplatin, cisplatin, Nedaplatin | Daping Hospital and the Research Institute of Surgery of the Third Military Medical University | Esophageal Squamous Cell Carcinoma | 02/24 | 12/24 | | |
NCT06170710: Postoperative CCRT Followed by Immunotherapy in High-Risk LA HNSCC |
|
|
| Recruiting | 2 | 173 | RoW | Anti-PD-1 monoclonal antibody, Postoperative CCRT | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Head and Neck Squamous Cell Carcinoma | 11/25 | 11/27 | | |
NCT04663035: Ablation Plus Tislelizumab Versus Ablation Alone for Intrahepatic Recurrent Early Stage HCC |
|
|
| Recruiting | 2 | 120 | RoW | Tislelizumab, Tislelizumab Injection, Ablation | Ming Zhao | Recurrent Hepatocellular Carcinoma | 12/23 | 12/25 | | |
ChiCTR2100043772: Clinical study of Tislelizumab combined with neoadjuvant chemotherapy for locally advanced esophageal squamous cell carcinoma |
|
|
| Recruiting | 2 | 30 | | islelizumab combined with neoadjuvant chemotherapy | Peking Union Medical College Hospital; Baiji Shenzhou (Shanghai) Biomedical Technology Co., Ltd; Peking Union Medical College Hospital, Baiji Shenzhou (Shanghai) Biomedical Technology Co., Ltd | Locally advanced esophageal carcinoma | | | | |
NCT05520814: PD-1 Inhibitors Plus Chemoradiotherapy for Metastatic Nasopharyngeal Carcinoma: an Open-label Single-arm, Phase II Trial |
|
|
| Active, not recruiting | 2 | 50 | RoW | PD-1 inhibitors, chemoradiotherapy | Sichuan Cancer Hospital and Research Institute | Nasopharyngeal Carcinoma, PD-1 Inhibitors, Chemoradiotherapy | 12/23 | 12/23 | | |
NCT04652440: Ablation Combined With PD-1 in HCC: Phase II Study |
|
|
| Recruiting | 2 | 30 | RoW | PD-1 monoclonal antibody, Tislelizumab, Radiofequencey or microwave ablation, ablation | Sun Yat-sen University | Hepatocellular Carcinoma | 12/23 | 06/24 | | |
LungMate-006, NCT04542369: Pilot Study of PD-1inhibitor (Tislelizumab) Plus Chemotherapy as Neoadjuvant Therapy for Limited-Stage Small-Cell Lung Cancer |
|
|
| Recruiting | 2 | 15 | RoW | Tislelizumab (BGB-A317) Plus Chemotherapy (Cisplatin/Carboplatin and Etoposide) | Shanghai Pulmonary Hospital, Shanghai, China | Small-cell Lung Cancer | 12/23 | 11/25 | | |
TNT, NCT05189730: Selected Chemotherapy Combined Immunotherapy Treated High Risk Patient After NCRT in Resected Locally Advanced ESCC |
|
|
| Recruiting | 2 | 80 | RoW | Tirelizumab, Paclitaxel, Carboplatin, Neoadiuvant radiotherapy | Sichuan Cancer Hospital and Research Institute | Esophageal Squamous Cell Carcinoma | 12/23 | 12/23 | | |
ChiCTR2100050076: Phase II clinical study of sorafenib combined with tislelizumab in the treatment of first-line unresectable hepatocellular carcinoma |
|
|
| Recruiting | 2 | 46 | | Sorafenib 400mg / bid orally, tislelizumab, 200mg / q3w intravenously | Cancer Hospital, Chinese Academy of Medical Sciences, Shenzhen Center; Cancer Hospital, Chinese Academy of Medical Sciences, Shenzhen Center, BeiGene (Beijing) Biotechnology Co., Ltd. | Hepatocellular carcinoma | | | | |
ChiCTR2100053292: Study on the evaluation of disgust in patients with episodic upper urinary tract urothelial carcinoma with high-risk non-metastatic muscle treated with tislelizhu |
|
|
| Not yet recruiting | 2 | 20 | China | Tilelizumab combined with cisplatin and gemcitabine | Shengjing Hospital Affiliated to China Medical University ; Shengjing Hospital Affiliated to China Medical University, BeiGene (Beijing) Biotechnology Co., Ltd. | Bladder urothelial carcinoma | | | | |
ChiCTR2200056067: HAIC Combined with Tislelizumab and Regorafenib for Advanced Intrahepatic Cholangiocarcinoma: A Single-Arm, Open-Label, Phase II Study |
|
|
| Not yet recruiting | 2 | 25 | China | HAIC + Tislelizumab + Regorafenib | The Fifth Medical Center of Chinese PLA General Hospital ; The Fifth Medical Center of Chinese PLA General Hospital, BeiGene, Ltd | Intrahepatic Cholangiocarcinoma | | | | |
| Recruiting | 2 | 20 | RoW | Tislelizumab Lenvatinib | Tianjin Medical University Second Hospital | Advanced Kidney Cancer | 12/23 | 12/25 | | |
SPECTRUM, NCT05253118: Relapsed or Refractory Primary Diffuse Large B-cell Lymphoma (DLBCL) of the Central Nervous System (CNS) |
|
|
| Recruiting | 2 | 28 | RoW | Tislelizumab, BGB-A317, Pemetrexed | Seoul National University Hospital, Gyeongsang National University Hospital, Kyunghee University Medical Center, Inje University Haeundae Paik Hospital, Chungnam National University Hospital | DLBCL | 12/25 | 02/26 | | |
NCT05638984: Low Dose Decitabine in Combination With Tirelizumab Comparison of Tirelizumab in the First-line Treatment of Advanced Esophageal Squamous Cell Carcinoma |
|
|
| Not yet recruiting | 2 | 60 | NA | Decitabine Injection, tirelizumab | Fudan University | PFS | 12/23 | 12/24 | | |
NCT05807776: Tislelizumab Monotherapy or Combined With Lenvatinib as Neoadjuvant Therapy for Resectable Hepatocellular Carcinoma. |
|
|
| Not yet recruiting | 2 | 50 | NA | Tislelizumab, Tislelizumab, Lenvatinib | Tianjin Medical University Cancer Institute and Hospital | Resectable Hepatocellular Carcinoma | 12/23 | 12/25 | | |
NCT05400902: HAIC Combined With Sintilimab and Bevacizumab for Unresectable Intrahepatic Cholangiocarcinoma |
|
|
| Recruiting | 2 | 17 | RoW | HAIC Combined with Tislelizumab and Apatinib | Binkui Li | Intrahepatic Cholangiocarcinoma | 12/23 | 12/23 | | |
NCT05582278: HAIC+Lenvatinib+Tislelizumab vs D-TACE+Lenvatinib+Tislelizumab for Unresectable HCC |
|
|
| Recruiting | 2 | 60 | RoW | D-TACE, D-TACE+lenvatinib+tislelizumab, HAIC, HAIC+Lenvatinib+tislelizumab, Lenvatinib, Targeted therapy, tislelizumab, PD-1 inhibitors | Wen Li | Unresectable Hepatocellular Carcinoma | 01/24 | 01/24 | | |
ChiCTR2000035642: Phase II Study of Tislelizumab Combined With Cetuximab and Irinotecan in the Treatment of Recurrent, Refractory Metastatic Colorectal Cancer |
|
|
| Completed | 2 | 33 | China | tislelizumab combined with cetuximab and irinotecan | Zhongshan Hospital Affiliated to Fudan University ; Zhongshan Hospital Affiliated to Fudan University, BeiGene Ltd provide tislelizumab | Colorectal cancer | | | | |
NCT05137886: PD-1 Inhibitor Combined With Decitabine Followed by ASCT as Second-line Therapy for Relapsed or Refractory Classic Hodgkin's Lymphoma |
|
|
| Recruiting | 2 | 47 | RoW | PD-1 inhibitor, decitabine, autologous stem cell transplantation | Institute of Hematology & Blood Diseases Hospital | Hodgkin Lymphoma, Adult, Relapse, Refractory Hodgkin Lymphoma | 01/24 | 01/25 | | |
NCT05435313: Fruquintinib Combined With Tislelizumab and HAIC in Patients With Advanced Colorectal Liver Metastases Cancer Who Failed Standard Therapy |
|
|
| Active, not recruiting | 2 | 39 | RoW | HAIC, Fruquintinib, Tislelizumab, Raltitrexed, Oxaliplatin, Irinotecan | Fudan University | Colorectal Cancer | 01/24 | 02/24 | | |
NCT06197438: Phase II Study of the Combination of Irinotecan and POF (POFI) and Tislelizumab in Advanced Gastric Cancer |
|
|
| Not yet recruiting | 2 | 36 | NA | Tislelizumab, Oxaliplatin, Levo-Leucovorin, 5-fluorouracil, Irinotecan Hydrochloride, Paclitaxel | Fujian Cancer Hospital | Gastric Cancer | 04/24 | 04/25 | | |
NCT06249750: Clinical Application of Near-infrared Whole Body Heat Shock Multimodal Technique in Treatment of Castration-resistant Prostate Cancer |
|
|
| Recruiting | 2 | 60 | RoW | Immunotherapy, Immune checkpoint inhibitor, ICI, Tislelizumab (BeiGene, China), Targeted therapy, RTK inhibitor, Anlotinib (CHIATAI TIANQING PHARMACEUTICAL GROUP, China), Hyperthermia, ET-SPACE whole body hyperthermia, near infrared irradiation, ET-SPACE™ (Shenzhen ET medical, China), heat stress | Pengyuan Liu | Metastatic Castration-resistant Prostate Cancer (CRPC) | 12/24 | 12/26 | | |
NCT06157996: Lenvatinib Plus Tislelizumab and CapeOX as First-Line Treatment for Advanced GC/GEJC With Positive PD-L1 and Low TMEscore |
|
|
| Recruiting | 2 | 92 | RoW | lenvatinib and tislelizumab plus CapeOX chemotherapy, tislelizumab plus CapeOX chemotherapy | Nanfang Hospital, Southern Medical University | Gastric Cancer | 08/26 | 08/26 | | |
NCT06211790: Proteomic Guided First-line Precision Treatment of Renal Clear Cell Carcinoma |
|
|
| Recruiting | 2 | 66 | RoW | Anlotinib, Everolimus and Tislelizumab | Fudan University | Kidney Cancer, Renal Cell Carcinoma, Renal Clear Cell Carcinoma | 12/25 | 12/26 | | |
NCT06233981: Phase II Study of Moderate-dose Hypofractionated RT Combined With Tislelizumab for HCC With Diffuse Tumor Thrombosis |
|
|
| Recruiting | 2 | 30 | RoW | Moderate-dose Hypofractionated Intensity-modulated Radiotherapy, Tislelizumab | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Hepatocellular Carcinoma, Radiotherapy, Tislelizumab, Tumor Thrombosis | 01/26 | 01/26 | | |
Truce-01, NCT04730219: Perioperative Tislelizumab Combined With Nab-Paclitaxel for Muscle-invasive Urothelial Bladder Carcinoma |
|
|
| Active, not recruiting | 2 | 48 | RoW | Tislelizumab, BGB-A317, Nab paclitaxel | Tianjin Medical University Second Hospital | Muscle Invasive Bladder Cancer, Urothelial Carcinoma | 02/24 | 07/24 | | |
Truce-02, NCT04730232: Tilelizumab Combined With Nab-Paclitaxel for High-Risk Non-Muscle-Invasive Urothelial Bladder Carcinoma Which is Not Completely Resectable |
|
|
| Recruiting | 2 | 63 | RoW | Tislelizumab, BGB-A317, Nab-paclitaxel | Tianjin Medical University Second Hospital | High-Risk, Non-Muscle Invasive Bladder Urothelial Carcinoma | 02/24 | 07/24 | | |
TRUCE-22, NCT05418309: Tilelizumab Combined With Nab-Paclitaxel for High-Risk Non-Muscle-Invasive Urothelial Bladder Carcinoma Which is Not Completely Resectable: a Multi-center Study |
|
|
| Recruiting | 2 | 63 | RoW | Tislelizumab Nab paclitaxel, BGB-A317 | Tianjin Medical University Second Hospital | High-Risk Non-Muscle Invasive Bladder Urothelial Carcinoma | 02/24 | 07/24 | | |
GASTO-1086, NCT05468242: Study of Tislelizumab for Locally Advanced Non-Small Cell Lung Cancer Following Neoadjuvant Chemotherapy Plus Tislelizumab ± Bevacizumab and Definitive Concurrent Chemoradiation Therapy |
|
|
| Recruiting | 2 | 116 | RoW | Neoadjuvant chemo-immunotherapy, Bevacizumab, Radiotherapy, Tislelizumab | Sun Yat-sen University | Stage III Non-small Cell Lung Cancer | 12/24 | 12/24 | | |
ChiCTR2200055516: A phase II clinical study of tislelizumab combined with neoadjuvant chemoradiotherapy for treatment locally advanced esophageal squamous cell carcinoma |
|
|
| Recruiting | 2 | 20 | | tiralizumab combined with neoadjuvant chemoradiotherapy | The Second Affiliated Hospital of Xi'an Jiaotong University; Level of the institution：, Self-funded | Esophageal squamous cell carcinoma | | | | |
CBPTMI, NCT05445648: Comprehensive Bladder Preservation Therapy on Patients With Muscle Invasive Bladder Cancer |
|
|
| Not yet recruiting | 2 | 65 | RoW | Tislelizumab Injection, BGB-A317, BeiGene, Transurethral resection of bladder tumor, Adjuvant radiotherapy | First Affiliated Hospital Xi'an Jiaotong University, BeiGene | Urinary Bladder Neoplasms | 02/24 | 02/26 | | |
NCT06211114: Study to Evaluate the Efficacy and Safety of Immunotherapy With Axitinib in Advanced Collecting Duct Carcinoma |
|
|
| Not yet recruiting | 2 | 30 | RoW | PD-(L)1 inhibitor, Axitinib | Peking University Cancer Hospital & Institute | Collecting Duct Carcinoma | 02/26 | 02/27 | | |
NCT06260553: Metronomic Oral Vinorelbine Combination With Tislelizumab in EGFR/ALK-negative Advanced NSCLC |
|
|
| Enrolling by invitation | 2 | 40 | RoW | tislelizumab and metronomic oral vinorelbine | Fujian Cancer Hospital | EGFR/ ALK-negative Advanced NSCLC | 02/25 | 08/25 | | |
NCT06259721: Anti-PD1 Monoclonal Antibody Combined With Nimotuzumab and Capecitabine in Patients With First-line Platinum-resistant Recurrent/Metastatic Nasopharyngeal Carcinoma |
|
|
| Recruiting | 2 | 22 | RoW | Anti-PD1 antibody, nimotuzumab and capecitabine | Jiangxi Provincial Cancer Hospital | Nasopharyngeal Carcinoma | 02/26 | 08/26 | | |
NCT06254521: The Effects of Neoadjuvant Tislelizumab Combined With Chemotherapy in Locally Advanced MSS Rectal Cancer |
|
|
| Recruiting | 2 | 60 | RoW | Tislelizumab combined with chemotherapy | First Affiliated Hospital of Guangxi Medical University | Rectal Cancer, Rectal Cancer Stage II, Rectal Cancer Stage III | 12/24 | 12/27 | | |
NCT05611879: Neoadjuvant of Tislelizumab Combined With Chemotherapy Followed by Surgery in Unresectable Stage Ⅲ NSCLC |
|
|
| Recruiting | 2 | 30 | RoW | Tislelizumab, Pemetrexed (Nonsquamous NSCLC) or Paclitaxel/Nab-paclitaxel(Squamous NSCLC), Carboplatin | Beijing Tsinghua Chang Gung Hospital | NSCLC, Stage III | 02/24 | 04/24 | | |
NCT04183088: Regorafenib Plus Tislelizumab as First-line Systemic Therapy for Patients With Advanced Hepatocellular Carcinoma |
|
|
| Recruiting | 2 | 125 | RoW | Tislelizumab+regorafenib for part 1;Tislelizumab+regorafenib for group 1 of part 2; Regorafenib for group 2 of part 2., Stivarga, BAY-73-4506, BGB-A317 | National Taiwan University Hospital, National Taiwan University Hospital, Yun-Lin Branch | Advanced Hepatocellular Carcinoma | 03/24 | 03/25 | | |
ChiCTR2000040760: Neoadjuvant chemotherapy combined with tislelizumab in the treatment of newly diagnosed ovarian cancer: a single arm, single center, phase II study |
|
|
| Not yet recruiting | 2 | 69 | China | carboplatin ;Paclitaxel ;tislelizumab | The First Affiliated Hospital of Suzhou University ; The First Affiliated Hospital of Suzhou University, sponsorship | newly diagnosed ovarian cancer | | | | |
POLAR-STAR, NCT05245474: Neoadjuvant Long-course Chemoradiation Plus PD-1 Blockade for Mid-low Locally Advanced Rectal Cancer |
|
|
| Recruiting | 2 | 186 | RoW | Long-course chemoradiation, with or without Tislelizumab (PD-1 inhibitor) | Beijing Friendship Hospital, Beijing Chao Yang Hospital, Xuanwu Hospital, Beijing, Beijing Hospital, Peking Union Medical College Hospital, Peking University First Hospital, Peking University People's Hospital, Peking University Cancer Hospital & Institute, BeiGene | Locally Advanced Rectal Cancer | 03/24 | 09/29 | | |
SITISVEAL, NCT05542342: Sitravatinib and Tislelizumab in Patients With Metastatic Uveal Melanoma With Liver Metastases. |
|
|
| Active, not recruiting | 2 | 16 | Europe | Tislelizumab, Sitravatinib Malate | Grupo Español Multidisciplinar de Melanoma, Mirati Therapeutics Inc., BeiGene | Uveal Melanoma | 12/23 | 05/24 | | |
NCT05758389: Tislelizumab Combined APF Chemotherapy in the Treatment of Locally Advanced Head and Neck Tumors |
|
|
| Recruiting | 2 | 29 | RoW | Tislelizumab, Paclitaxel (albumin-bound type), Cisplatin, 5-FU | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | Head and Neck Tumors | 06/24 | 06/25 | | |
HAI-TL, NCT06210334: HAIC Combine Tislelizumab and Lenvatinib in the Treatment of HCC With Type IV (Vp4) Portal Vein Tumor Thrombus |
|
|
| Not yet recruiting | 2 | 54 | RoW | Tislelizumab, PD-1, Lenvatinib, TKI | Li Xiao Wei | Hepatocellular Carcinoma With PVTT | 07/25 | 01/26 | | |
NCT06323369: Tislelizumab Combined With Chemotherapy Followed by Surgery Versus Up-front Surgery in Resectable Clinically Node-negative Head and Neck Squamous Cell Carcinoma |
|
|
| Recruiting | 2 | 154 | RoW | Tislelizumab（neoadjuvant）, Cisplatin （neoadjuvant）, Nab-paclitaxel （neoadjuvant）, Surgical resection, Cisplatin（adjuvant）, Tislelizumab（adjuvant）, Radiation, Carboplatin（neoadjuvant）, Carboplatin（adjuvant） | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Head and Neck Squamous Cell Carcinoma | 03/29 | 09/29 | | |
NCT06253598: Efficacy and Safety of Intratumoral Injection of Recombinant Human Adenovirus Type 5 Combined With Tislelizumab and Lenvatinib in the Treatment of Advanced Hepatocellular Carcinoma |
|
|
| Not yet recruiting | 2 | 30 | NA | Recombinant Human Adenovirus Type 5, H101, Lenvatinib, Tislelizumab | First Affiliated Hospital Bengbu Medical College | Hepatocellular Carcinoma | 12/25 | 12/26 | | |
AdvanTIG-206, NCT04948697: A Study Investigating the Efficacy and Safety of Ociperlimab and Tislelizumab and BAT1706 Combinations in Patients With Advanced HCC |
|
|
| Completed | 2 | 94 | RoW | Ociperlimab, BGB-A1217, Tislelizumab, BGB-A317, BAT1706, Bevacizumab Injection | BeiGene | Advanced Hepatocellular Carcinoma | 02/24 | 02/24 | | |
NeoRTPC02, NCT05343325: The Efficacy and Safety of Neoadjuvant Low-dose Radiotherapy Combined With Chemoimmunotherapy in Locally Advanced HNSCC |
|
|
| Recruiting | 2 | 25 | RoW | Tislelizumab, Albumin-bound paclitaxel, Cisplatin, Low-dose radiotherapy | Fifth Affiliated Hospital, Sun Yat-Sen University, Dongguan People's Hospital | Head and Neck Squamous Cell Carcinoma, Neoadjuvant Treatment | 03/24 | 03/27 | | |
ChiCTR2200057978: Hepatic Artery Infusion Chemotherapy (HAIC) Plus Tislelizumab for Neoadjuvant Treatment of Patients with HCC With Portal Vein Carcinoma Thrombosis |
|
|
| Not yet recruiting | 2 | 30 | China | HAIC plus Tislelizumab | The Third Affiliated Hospital of Naval Medical University ; The Third Affiliated Hospital of Naval Medical University, Beijing Red lilac development of public welfare center | Hepatocellular Carcinoma | | | | |
ChiCTR2100045112: Tirelizumab combined with amlotinib for second-line treatment of advanced urothelial carcinoma II Phase II clinical study |
|
|
| Recruiting | 2 | 48 | China | Tilelizumab combined with Anlotinib | Yanbian University Hospital ; Yanbian University Hospital, self-raised | Urothelial carcinoma | | | | |
NCT04860674: A Prospective Study of PD-1 Inhibitor Combined With ICE in the Treatment of Relapsed/Refractory Gray Area Lymphoma |
|
|
| Not yet recruiting | 2 | 20 | NA | PD-1 inhibitor +ICE, Icyclophosphamide, carboplatin, etoposide | Zhejiang Cancer Hospital | Gray Zone Lymphoma, Relapse/Recurrence, Chemotherapy Effect | 04/24 | 04/24 | | |
NCT05303038: Cryoablation Combined With Tirelizumab and Bevacizumab in Liver Metastatic TNBC Patients Failed by Multiline Therapy |
|
|
| Recruiting | 2 | 15 | RoW | Cryoablation Combined with Tirelizumab and Bevacizumab | Fudan University | Metastatic Breast Cancer in the Liver | 04/24 | 04/24 | | |
NCT05401279: Bladder Sparing Treatment of Tislelizumab, Gemcitabine and Cisplatin for Patients With PD-L1 Positive Muscle Invasive Bladder Cancer |
|
|
| Recruiting | 2 | 20 | RoW | Tislelizumab, Gemcitabine, Cisplatin | RenJi Hospital | Urothelial Carcinoma Bladder, PD-1 Inhibitor | 04/24 | 05/25 | | |
NCT05278351: Tislelizumab Plus Cetuximab and Irinotecan vs Third-line Standard-of-care in Refractory mCRC |
|
|
| Recruiting | 2 | 87 | RoW | Tislelizumab Combined With Cetuximab and Irinotecan, TEC, Third-line regimens | Shanghai Zhongshan Hospital | Colorectal Neoplasms Malignant | 04/24 | 12/25 | | |
ChiCTR2200065746: Clinical study of chidamide combined with tislelizumab in the treatment of advanced osteosarcoma |
|
|
| Not yet recruiting | 2 | 23 | China | chidamide combined with tislelizumab | Beijing Jishuitan Hospital ; Beijing Jishuitan Hospital, self-funded | osteosarcoma | | | | |
NCT06238167: Tislelizumab Plus Chemotherapy as Postoperative Adjuvant Therapy in Elderly Patients With LA GC/GEJC |
|
|
| Not yet recruiting | 2 | 40 | NA | Tislelizumab, S-1 therapy, low dose SOX therapy | First Affiliated Hospital of Wenzhou Medical University | Gastric Cancer | 12/26 | 12/28 | | |
NCT06202716: Cadonilimab Plus CapeOX as First-Line Treatment for Advanced GC/GEJC With High TMEscore |
|
|
| Not yet recruiting | 2 | 50 | RoW | Cadonilimab plus CapeOX chemotherapy | Nanfang Hospital, Southern Medical University | Gastric Cancer | 04/26 | 04/26 | | |
NCT06356597: Tislelizumab With Fruquintinib, Metronidazole, in Mismatch Repair-proficient or Microsatellite Stability, Advanced Colorectal Cancer: a Multicenter, Single Arm, Clinical Trial |
|
|
| Recruiting | 2 | 25 | RoW | Tislelizumab with Fruquintinib, Metronidazole | Jing-yuan Fang, MD, Ph. D | Colorectal Cancer | 12/25 | 12/27 | | |
| Recruiting | 2 | 40 | RoW | Rezvilutamide, Goserelin Microspheres for Injection, Docetaxel, Pamiparib, Cisplatin, Tislelizumab | The First Affiliated Hospital of Xiamen University | Locally Advanced Prostate Cancer, Oligometastatic Prostate Cancer | 04/26 | 04/29 | | |
| Recruiting | 2 | 90 | RoW | Tislelizumab (BGB-A317) with chemoradiotherapy | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Esophagus Cancer | 12/26 | 12/27 | | |
NCT05799443: Efficacy and Safety of SBRT Followed by Tislelizumab Plus Cetuximab and Irinotecan in Patients With Previously Treated RAS Wild-type Advanced Refractory Colorectal Cancer |
|
|
| Not yet recruiting | 2 | 23 | NA | Tislelizumab, Irinotecan Hydrochloride, cetuximab, SBRT | Fujian Cancer Hospital | Colorectal Cancer | 04/24 | 04/25 | | |
NCT06353360: TTField in Combination With TMZ and Tislelizumab in The Treatment of Newly Diagnosed Glioblastoma. |
|
|
| Not yet recruiting | 2 | 30 | NA | Tumor Treating Fields, Tislelizumab, Temozolomide (TMZ) | Jiangsu Healthy Life Innovation Medical Technology Co., Ltd | Glioblastoma Multiforme | 07/25 | 03/26 | | |
NCT06354140: PPIO-008S-1 Combined With Tislelizumab in Patients With Primary Residual Node-negative Esophageal Squamous Cell Carcinoma (ESCC) After Radical Resection With Neoadjuvant Immunotherapy Combined With Chemotherapy, PHASE II STUDY |
|
|
| Recruiting | 2 | 45 | RoW | Tegafur, tislelizumab | Daping Hospital and the Research Institute of Surgery of the Third Military Medical University | Postoperative Assistance for Esophageal Squamous Cell Carcinoma With Negative Lymph Nodes | 04/27 | 04/28 | | |
NeoSCLC-001, NCT06375109: PD-L1/PD-1 Inhibitors Plus Chemotherapy Versus Chemotherapy Alone for the Neoadjuvant Treatment of Limited-stage SCLC |
|
|
| Not yet recruiting | 2 | 60 | NA | Tislelizumab, Carboplatin injection, Cisplatin injection, Etoposide injection | Beijing Chest Hospital, Capital Medical University | Limited-stage Small-cell Lung Cancer | 04/27 | 04/29 | | |
NCT06366945: Tirelizumab in Combination With Carboplatin and Polymeric Micellar Paclitaxel for Neoadjuvant Therapy in cN+ HNSCC |
|
|
| Not yet recruiting | 2 | 85 | NA | Carboplatin, Tislelizumab, Polymeric Micellar Paclitaxel, Surgical Resection of Primary +/- Neck Dissection, Post-operative radiation therapy | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Head and Neck Squamous Cell Carcinoma, Head and Neck Cancer, HNSCC, Head Cancer Neck | 12/26 | 05/29 | | |
| Not yet recruiting | 2 | 134 | RoW | Tislelizumab, SOX/XELOX | Xiangdong Cheng, Liaoning Tumor Hospital & Institute, Shanxi Province Cancer Hospital, Sichuan Cancer Hospital and Research Institute, The Second Affiliated Hospital of Harbin Medical University | Gastric Cancer | 03/26 | 03/28 | | |
ChiCTR2200059948: DEB-TACE + GP chemotherapy combined with Tislelizumab in the first-line treatment of advanced and or unresectable intrahepatic cholangiocarcinoma：A single arm, prospective, phase II study |
|
|
| Not yet recruiting | 2 | 26 | China | DEB-TACE+GP chemotherapy combined with Tislelizumab | Fujian Cancer Hospital ; Fujian Cancer Hospital, nvestigator initiated clinical trials | advanced and or unresectable intrahepatic cholangiocarcinoma | | | | |